vendredi 29 juin 2018

Onco Actu du 29 juin 2018

1. Biologie

Molecular brake on human cell division prevents cancer [Karolinska Institutet]

Unlocking new insight into brain tumours using neuroscience [Cancer Research UK]

3.4 Chimioprévention

Vitamin D and the relationship to colon cancer [Science-Based Medicine]

3.8 Prévention - Alimentation

Research shows that diet can lower risk of recurrence in stage III colon cancer [Dana-Farber Cancer Institute]

4. Dépistage, diagnostic et pronostic

For Some Bladder Cancer Patients, Simple Test Could Reduce Overtreatment, Ease High Cost [Georgetown University]

5.1 Traitements - Pré-clinique

Why Not Target DNA? Well. . . [In the Pipeline]

Resistance to prostate-cancer treatment is driven by immune cells [Nature]

5.10 Traitements - Essais

Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer [NCI]

Metastasis-free Survival — A New End Point in Prostate Cancer Trials [NEJM]

5.12 Immunothérapies

Penn Study Reveals Secrets of “Hot” and “Cold” Pancreatic Cancer Tumors [Penn Medicine]

Immunotherapy drug for skin disease could boost hormone treatment for prostate cancer [Institute of Cancer Research]

5.2 Pharma

Acceleron’s Blood Drug Hits Phase 3 Goals, Paves Way for FDA Filing [Xconomy]

Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes [Acceleron]

Acceleron blood disease drug hits goal in pivotal clinical trial [STAT]

Sarcoma expert George Demetri grades the latest statement on Nanobiotix’s late-stage drug NBTXR3 [EndPoints]

5.2.3 Pharma - économie

ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round [FierceBiotech]

Merck has hardened its defenses against cyberattacks like the one last year that cost it nearly $1B [FiercePharma]

5.3 Traitements - FDA, EMA, NICE...

FDA Drafts Guidance on Radiopharmaceuticals for Oncology [RAPS]

FDA Details Hiring Challenges [Biocentury]

5.4 Traitements - Economie

Roche's Alecensa secures NICE approval in NSCLC after topping Pfizer's Xalkori [Pharmafile]

6.1 Observation

Survivors of Childhood Extracranial Malignancy Who Received Chemotherapy Are Likely to Have Long-Term Neurological Toxicity [ESMO]